Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Cash from Investing Activities (2016 - 2025)

Abeona Therapeutics (ABEO) has 14 years of Cash from Investing Activities data on record, last reported at -$64.6 million in Q3 2025.

  • For Q3 2025, Cash from Investing Activities fell 947.95% year-over-year to -$64.6 million; the TTM value through Sep 2025 reached $114.4 million, up 345.45%, while the annual FY2024 figure was -$39.2 million, 18965.38% down from the prior year.
  • Cash from Investing Activities reached -$64.6 million in Q3 2025 per ABEO's latest filing, down from $155.9 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $155.9 million in Q2 2025 and bottomed at -$64.6 million in Q3 2025.
  • Average Cash from Investing Activities over 5 years is $5.2 million, with a median of $2.2 million recorded in 2023.
  • Peak YoY movement for Cash from Investing Activities: surged 483.84% in 2021, then tumbled 1236.63% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at $8.0 million in 2021, then tumbled by 416.16% to -$25.3 million in 2022, then surged by 145.59% to $11.5 million in 2023, then skyrocketed by 63.73% to $18.9 million in 2024, then crashed by 442.38% to -$64.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$64.6 million in Q3 2025, $155.9 million in Q2 2025, and $4.2 million in Q1 2025.